Table 3 Results of secondary seed statement review
Revised seed statement | Agreement (Rated as 7–9, or “highly appropriate”) |
|---|---|
Secondary pharmacological management may consist of tramadol, when tolerated and in the absence of contraindication(s) | 9/11 (82.0%) |
Secondary pharmacological management may consist of duloxetine, when tolerated and in the absence of contraindication(s) | 7/11 (64.0%)* |